AstraZeneca: FDA Extends PDUFA Date Related To NDA For Camizestrant

(RTTNews) - AstraZeneca (AZN, AZN.L, ZEG.DE, AZN.ST) said the FDA has informed that it will extend the PDUFA date to review additional data requested to support the New Drug Application for camizestrant in combination with a cyclin-dependent kinase 4/6 inhibitor for the 1st-line https://www.nasdaq.com/articles/astrazeneca-fda-extends-pdufa-date-related-nda-camizestrant